Gene therapy for high grade gliomas

Bibliography

• KROLL RA, NEUWELT EA: Outwitting the blood-brainbarrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery (1998) 42:1083–1100.
   PubMed Web of Science ®Google Scholar
• MCALLISTER LD, DOOLITTLE ND, GUASTADISEGNI PE etal.: Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosur-gery (2000) 46(1):51–61.
   Google Scholar
• BREM H, PIANTADOSI S, BURGER PC et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent g,liomas. Lancet (1995) 345:1008–1012.
   PubMed Web of Science ®Google Scholar
• MOOLTEN F: Tumor sensitivity conferred by inserted herpes thymidine kinase genes: paradigm for prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
   PubMed Web of Science ®Google Scholar
• •• Experimental background for prodrug activation system.
   Google Scholar
• ELSHAMI AA, SAAVEDRA A, ZHANG H et al.: Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. (1996) 3(1):85–92.
   PubMed Web of Science ®Google Scholar
• • Demonstrates the contribution of gap junctions to the bystander effect.
   Google Scholar
• BARBE D, HARDIN J, SADELAIN M, GAGE FH: Development of anti-tumor immunity following thymidine-kinase mediated killing of experimental brain tumors. Proc. Natl Acad. Sci. (USA)(1994) 91:4348–4352.
   PubMed Web of Science ®Google Scholar
• • Demonstration of immune effect of gene therapy.
   Google Scholar
• BERENSTEIN M, ADRIS S, LEDDA F et al.: Different efficacy of in vivo herpes simplex virus thymidine kinase gene transduction and ganciclovir treatment on the inhibition of tumor growth of murine and human melanoma cells and ratglioblastoma cells. Cancer Gene Ther. (1999) 6(4):358–366.
   PubMed Web of Science ®Google Scholar
• RAM Z, CULVER KW, OSHIRO M et al.: Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med.(1997) 3:1354–1361.
   PubMed Web of Science ®Google Scholar
• •• The first human trial of gene therapy for brain tumour.Provides evidence for the distribution of retroviral vectors following intra tumour injection.
   Google Scholar
• IZQUIERDO M, MARTIN V, DE FELIPE P et al.: Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. (1996) 3:491–495.
   Google Scholar
• IZQUIERDO M, CORTES ML, MARTIN V et al.: Gene therapy in brain tumors: implication of the size of glioblastoma on its curability. Acta Neurocbir. (1997) Suppl. 68:111–117.
   Google Scholar
• KLATZMANN D, VALERY CA, BENSIMON GB et al.: A Phase I/II study of herpes simplex virus Type 1 thymidine kinase'suicide' gene therapy for recurrent glioblastoma. Hum. Gene Ther. (1998) 9(17):2595–2604.
   PubMed Web of Science ®Google Scholar
• SHAND N, WEBER F, MARIANI L et al.: A Phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforrne by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum. Gene Ther. (1999) 10:2325–2335.
   PubMed Web of Science ®Google Scholar
• LONG Z, LI LP, GROOMS T, LOCKEY C et al.: Biosafety monitoring of patients receiving intracerebral injections of murine retroviral producer cells. Hum. Gene Ther. (1998) 9:1165–1171.
   PubMed Web of Science ®Google Scholar
• LONG Z, LU P, GROOMS T et al.: Molecular evaluation ofbiopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy. Hum. Gene Tiger. (1999) 10:733–740.
   PubMed Web of Science ®Google Scholar
• DONAHUE RE, KESSLER SW, BODICE D et al.: Helpervirus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp. Med.(1992) 176:1125–1135.
   PubMed Web of Science ®Google Scholar
• RAINOV NG: A Phase BI clinical evaluation of herpessimplex virus Type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblas-toma multiforme. Hum. Gene Tiger. (2000) 11:2389–2401.
   PubMed Web of Science ®Google Scholar
• WEITZMAN MD, WILSON JM, ECK SL: Adenovirus vectors in cancer gene therapy. In : The Internet Book of Gene Therapy: Cancer Therapeutics, Sobel RE and Scanlon KJ (Eds.) Appleton and Lange (1995).
   Google Scholar
• SMITH JG, RAPER SE, WHEELDON EB et al.: Intracranial administration of adenovirus expressing HSVTK in combination with ganciclovir produces a dose dependent, self-limiting inflammatory response. Hum. Gene Ther. (1997) 8 (8):043–054.
   Web of Science ®Google Scholar
• BEHBAKHT K, BENJAMIN I, CHIU H-C et al.: Adenovirus-medicated gene therapy of ovarian cancer in a mouse model. Am. J. Obstet. Gynecol. (1996) 75:1260–1265.
   Web of Science ®Google Scholar
• TRASK TW, TRASK RP, AGUILAR-CORDOVA E et al.: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors. Molecular Ther. (2000) 1:195–203.
   PubMed Web of Science ®Google Scholar
• ECK SL, ALAVI JB, ALAVI A et al.: Treatment of advancedCNS malignancies with the recombinant adenovirus H501ORSVIK: A Phase I trial. Hum. Gene Ther. (1996) 7:1465–1482
   PubMed Web of Science ®Google Scholar
• ALAVI JB, JUDY K, ALAVI A et al.: Phase I trial of genetherapy in primary brain tumors. Proc. Amer. Soc. Clin. Oncol. (1998) 17:379a.
   Google Scholar
• PUUMALAINEN A-M, VAPALAHTI M, AGRAWAL R et al.:b-Galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. (1998) 9:1769–1774.
   PubMed Web of Science ®Google Scholar
• SUBACH BR, WITHAM TF, KONDZIOLKA D, LUNSFORDLD, BOZIK M, SCHIFF D: Morbidity and survival after 1, 3-bis(2-chloroethyl)-1-nitrosourea wafer implanta-tion for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery (1999) 45(1):17–22.
   PubMed Web of Science ®Google Scholar
• TOURAINE RL, VAHANIAN N, RAMSEY WJ, BLAESE RM: Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Hum. Gene Ther. (1999) 9(16):2385–2391.
   Web of Science ®Google Scholar
• KOKORIS MS, SABO P, ADMAN ET et al.: Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther. (1999) 6(8):1415–1426.
   PubMed Web of Science ®Google Scholar
• TJUVAJEV JG, AVRIL N, OKU T et al.: Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. (1998) 58:4333–4341.
   PubMed Web of Science ®Google Scholar
• •• Demonstrates imaging of HSVtk expression using radiola-belled GCV.
   Google Scholar
• ALAUDDIN MM, SHAHINIAN A, KUNDU RK, GORDON EM. CONTI PS:Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methylguanine ([18F1-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nuc. Medicine & Biology (1999) 26(4):371–376.
   PubMed Web of Science ®Google Scholar
• GAMBHIR SS, BARRIO JR, PHELPS ME et al.: Imagingadenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl. Acad. Sci. USA (1999) 96(5):2333–2338.
   PubMed Web of Science ®Google Scholar
• HUSTINX R, SHIUE CY, ZHUANG HM et al.: Monitoringherpes simplex virus thymidine kinase gene transfer to tumors with 18F-FHPG and PET. Eur. J. Nuc. Med. (2001) 28:5–12.
   PubMedGoogle Scholar
• FRANKEL RH, BAYONA W, KOSLOW M et al.: P53 mutation in human malignant g,liomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res. (1992) 52:1427–1433.
   PubMed Web of Science ®Google Scholar
• VELCULESCU YE, EL-DIERY WS: Biological and clinicalimportance of the p53 suppressor gene. Clin. Chem. (1996) 42:858–868.
   PubMed Web of Science ®Google Scholar
• • Summarises the role of p53 in common tumours.
   Google Scholar
• HSIAO M, TSE V, CARMEL J et al.: Intracavitary liposome-mediated p53 gene transfer into glioblas-toma with endogenous wild-type p53 in vivo results in tumor suppression and long term survival. Biochem. Biophys. Res. Commun. (1997) 233:359–364.
   PubMed Web of Science ®Google Scholar
• VAN MEIR EG, POLVERINI PJ, CHAZIN VE eta/.: Release of an inhibitor of angiogenesis upon induction o fwild-type p53 expression in glioblastoma cells. Nature. Genet. (1994) 8:171–176.
   Google Scholar
• NISHIZAKI M, FUJIWARA T, TANIDA T et al.: Recombi-nant adenovirusexpressing wild-type p53 is antiangio-genic: a proposed mechanism for bystander effect. Clin. Cancer Res (1999) 5(5):1015–1023.
   PubMed Web of Science ®Google Scholar
• ROTH JA: Restoration of tumor suppressor gene expression for cancer. Forum (1998) 91:368–376.
   Google Scholar
• LANG FF, YUNG WKA, RAJU U, LIBUANO F, TERRY NHA,TOFILON PJ: Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurgery (1998) 89:125–132.
   PubMed Web of Science ®Google Scholar
• PIROLLO KF, HAO Z, RAIT A et al.: p53 mediated sensiti-zation of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene (1997) 14: 1735-1746.
   Google Scholar
• GRIDLEY DS, ANDRES ML, LI J, TIMIRYASOVA T, CHEN B, FODOR I: Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy. Int. J. Oncology (1998) 13:1093–1098.
   PubMed Web of Science ®Google Scholar
• HEISE C, URN DH: Replication-selective adenoviruses as oncolytic agents. J. Clin. Invest. (2000) 105:847–851.
   PubMed Web of Science ®Google Scholar
• MINETA T, RABKIN SD, YAZAKI T, HUNTER WD, MARTUZA RL: Attenuated multi-mutated herpes simplex virus-I for the treatment of malignant gliomas. Nature Med. (1995) 1:938–943.
   PubMed Web of Science ®Google Scholar
• HEISE C, SAMPSON-JOHANNES A, WILLIAMS A, MC CORMICK F, VONHOFF DD, KIRN DH: ONYX-015, an EIS gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapy agents. Nature Med. (1997) 3:639–643.
   PubMed Web of Science ®Google Scholar
• ROTHMANN T, HENGSTERMANN A, WHITAKER NJ, SCHEFFNER M, ZUR HAUSEN H: Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells./ Virol. (1998) 72:9470–9478.
   PubMed Web of Science ®Google Scholar
• HARADA JN, BERK AJ: p53-Independent and -depen-dent requirementsfor EIB-55K in adenovirus Type 5 replication. J. Virol. (1999) 73:5333–5344.
   PubMed Web of Science ®Google Scholar
• NEMUNAITIS J, GANLY I, KHURI F eta/.: Selective replica-tion and oncolysis in p53 mutant tumors with ONYX-015, an EIS-551(D gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. (2000) 60:6359–6366.
   Google Scholar
• MARTUZA RL, MALICK A, MARKERT JM, RUFFNER KL,COEN DM: Experimental therapy of human glioma by means of genetically engineered virus mutant. Science (1991) 252:854–856.
   PubMed Web of Science ®Google Scholar
• MARTUZA RL: Conditionally replicating herpes vectorsfor cancer therapy. J. Clin. Invest. (2000) 105841–846.
   Google Scholar
• • Updated summary of the use of herpes vectors as oncolytic agents.
   Google Scholar
• RAMPLING R, CRUICKSHANK G, MACLEAN A, BROWN M:Therapeutic replication-competent herpes virus. Nature Med. (1998) 4:133 (letter).
   Google Scholar
• RAINOV NG, KRAMM CM, BANNING U et al.: Immuneresponse inducedby retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients withglioblastoma multiforme. Gene Ther. (2000) 7:1853–1858.
   PubMed Web of Science ®Google Scholar
• RUSSELL SJ: Replicating vectors for gene therapy ofcancer: risks, limitations and prospects. European J. Cancer (1994) 30:1165–1171.
   Web of Science ®Google Scholar
• PALU G, CAVAGGIONI A, CALVI P et al.: Gene therapy ofglioblastoma multiforme via combined expression of suicide and cytokinegenes: a pilot study in humans. Gene Ther. (1999) 6:330–337.
   PubMed Web of Science ®Google Scholar
• ZHU J, ZHANG L, HANISCH UK, FELGNER PL, RESZKA R: Acontinuous intracerebral gene delivery system for in vivo liposome-mediated gene therapy. Gene Ther. (1996) 3:472–476.
   PubMed Web of Science ®Google Scholar
• IZQUIERDO M, MARTIN V, DE FELIPE P et al.: Humanmalignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. (1996) 3:491–495.
   Google Scholar
• LASKE DW, YOULE RJ, OLDFIELD EH: Tumor regressionwith regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nature Med. (1997) 3:1362–1368.
   PubMed Web of Science ®Google Scholar
• KROLL RA, PAGEL MA, MULDOON LL, ROMAN-GOLDSTEIN S, NEUWELT EA: Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery (1996) 38:746–752.
   PubMed Web of Science ®Google Scholar
• NILAVER, G, MULDOON LL, KROLL RA et al.: Delivery ofherpes virus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption. Proc. Natl. Acad. Sci. USA (1995) 92(20:9829–9833.
   PubMed Web of Science ®Google Scholar
• ECK SL, ALAVI JB, JUDY KD et al.: Clinical protocol.Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expresssing human interferon-beta (H5.010CMVIATN-B): A Phase I trial. Hum. Gene Ther. (2001) 12:97–113.
   Google Scholar
• QIN XQ, TAO N, DERGAY A et al.: Interferon-beta genetherapy inhibits tumor formation and causes regres-sion of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95(24):14411–14416.
   PubMed Web of Science ®Google Scholar
• HUBER BE, AUSTIN EA, RICHARDS CA, DAVIS ST, GOODSS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine dearninase. Proc. Natl. Acad. Sci. USA (1994) 91(17):8302–8306
   PubMed Web of Science ®Google Scholar
• DONG Y, WEN P, MANOME Y ET AL.: In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deanainase gene sensitizes glioma cells to 5-fluorocytosine. Hum. Gene Ther. (1996) 7(6):713–720.
   Google Scholar
• ADACHI Y, TAMIYA T, TERADA K et al.: Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine dearninase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Hum. Gene Ther. (2000) 11:77–89.
   PubMed Web of Science ®Google Scholar
• AGHI M, KRAMM CM, BREAKEFIELD XO: Folylpolyglu-tamyl synthetase gene transfer and glioma antifolate sensitivity. J. Natl. Cancer Inst. (1999) 91:1233–1241.
   PubMed Web of Science ®Google Scholar
• AGHI M, KRAMM CM, CHOU TC, BREAKEFIELD XO, CHIOCCA EA: Synergistic anticancer effects of ganciclovir/thymidinekinaseand5-fluorocytosine/cytosine dearninase gene therapies. J. Natl. Cancer Inst. (1998) 4:(5):370–80.
   Web of Science ®Google Scholar
• AGHI M, CHOU TE, SULING K: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. (1999) 59:3861–3865.
   PubMed Web of Science ®Google Scholar
• MARKERT JM, MEDLOCK MD, RABKIN SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. (2000) 7(10):807–74.
   Web of Science ®Google Scholar
• LANG FF, YUNG WK, SAWAYA R, TOFILON PJ: Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery (1999) 45:1093–1104.
   PubMed Web of Science ®Google Scholar